Back
Astellas Pharma 10K Form
Sell
22
ALPMY
Astellas Pharma
Last Price:
11.97
Seasonality Move:
3.49%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ALPMY News And Ratings
See the #1 stock for the next 7 days that we like better than ALPMY
ALPMY Financial Statistics
Sales & Book Value
| Annual Sales: | $11.25B |
|---|---|
| Cash Flow: | $42.67M |
| Price / Cash Flow: | 20.99 |
| Annual Sales: | $6.11 |
| Price / Book: | 2.01 |
Profitability
| EPS (TTM): | 0.12530 |
|---|---|
| Net Income (TTM): | $225.47M |
| Gross Margin: | $9.11B |
| Return on Equity: | 1.99% |
| Return on Assets: | 1.14% |
Astellas Pharma Earnings Forecast
Key Astellas Pharma Financial Ratios
- The Gross Profit Margin over the past 20 years for ALPMY is 81.01%.
- The Selling, General & Administrative Expenses for ALPMY have been equal to 41.50% of Gross Profit Margin.
- The Research & Development expenses have been 18.18% of Revenue.
- The Interest Expense is 8.89% of Operating Income.
- The Net Earning history of ALPMY is 6.50% of Total Revenues.
- Per Share Earnings over the last 20 years have been positive in 10 years.
Astellas Pharma Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | OTCM |
|---|---|
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Current Symbol: | ALPMY |
| Website: | astellas.com |
Debt
| Debt-to-Equity Ratio: | 0.54 |
|---|---|
| Current Ratio: | 0.96 |
| Quick Ratio: | 0.75 |
Price-to-Earnings
| Trailing P/E Ratio: | 30.61 |
|---|---|
| Forward P/E Ratio: | 0 |
ALPMY Technical Analysis vs Fundamental Analysis
Sell
22
Astellas Pharma (ALPMY)
is a Sell
Is Astellas Pharma a Buy or a Sell?
-
Astellas Pharma stock is rated a Sell
The current Astellas Pharma [ALPMY] share price is $12.26. The Score for ALPMY is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.